View More Recent Stories

Sep 27, 2024 08:05AM Savara (SVRA) Announces Expanded Access Program for Molgramostim Inhalation Solution for Patients with Autoimmune Pulmonary Alveolar Proteinosis

Sep 24, 2024 08:05AM Savara (SVRA) Appoints Braden Parker as Chief Commercial Officer

Sep 9, 2024 06:13AM Savara (SVRA) Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution

Sep 7, 2024 08:00PM Here's the list of biotech stocks that have key data catalysts in 2025

Aug 15, 2024 08:05AM Savara (SVRA) to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis

Aug 13, 2024 07:21AM Oppenheimer Reiterates Outperform Rating on Savara (SVRA)

Aug 12, 2024 04:29PM Savara (SVRA) Misses Q2 EPS by 2c

Jun 28, 2024 08:50AM Savara (SVRA) Announces Pricing of $100.0 Million Underwritten Offering of Common Stock

Jun 27, 2024 06:05AM Savara (SVRA) PT Raised to $10 at H.C. Wainwright

Jun 27, 2024 05:39AM Savara (SVRA) PT Raised to $10 at JMP Securities

Jun 26, 2024 02:09PM Savara (SVRA) PT Raised to $15 at Oppenheimer

Jun 26, 2024 06:32AM Savara (SVRA) Reports Molgramostim Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2

Jun 10, 2024 06:22AM Piper Sandler Reiterates Overweight Rating on Savara (SVRA)

View More Recent Stories